Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002189
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
Paclitaxel in Advanced Refractory Kaposis Sarcoma AIDS-KS A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals
Sponsor:
Baker Norton Pharmaceuticals
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Paclitaxel in Advanced Refractory Kaposis Sarcoma AIDS-KS A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals
Status:
COMPLETED
Status Verified Date:
1998-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine response rate median time to tumor progression qualitative and quantitative toxicity and reversibility of toxicity in patients with advanced refractory AIDS-associated Kaposis sarcoma KS administered a 3-hour infusion of paclitaxel every 14 days To evaluate the clinical benefit of paclitaxel in this patient population by evaluating self-reported responses to the Symptom Distress Scale and by documenting and evaluating any changes in their lymphedema pain and disfiguring facial lesions
Detailed Description:
Patients are treated with paclitaxel intravenously every 2 weeks up to 10 courses Patients who achieve a complete response receive 2 additional courses those who achieve partial response or stabilization continue therapy until progression
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| IX-110-081 | None | None | None |